Amplify Weight Loss Drug & Treatment ETF (THNR) To Go Ex-Dividend on December 30th

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) announced an annual dividend on Monday, December 29th. Shareholders of record on Tuesday, December 30th will be given a dividend of 0.4132 per share on Wednesday, December 31st. This represents a yield of 162.0%. The ex-dividend date of this dividend is Tuesday, December 30th.

Amplify Weight Loss Drug & Treatment ETF Trading Down 1.9%

Shares of Amplify Weight Loss Drug & Treatment ETF stock opened at $25.44 on Wednesday. The firm’s 50 day simple moving average is $24.80 and its two-hundred day simple moving average is $23.73. The firm has a market capitalization of $2.80 million, a price-to-earnings ratio of 24.31 and a beta of 0.61. Amplify Weight Loss Drug & Treatment ETF has a 12-month low of $18.56 and a 12-month high of $26.30.

Hedge Funds Weigh In On Amplify Weight Loss Drug & Treatment ETF

A hedge fund recently raised its stake in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC raised its position in shares of Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) by 5.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 24,891 shares of the company’s stock after purchasing an additional 1,215 shares during the quarter. Jane Street Group LLC owned 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 at the end of the most recent reporting period.

About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.